Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy
- 27 May 2009
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 69 (12) , 1325-1333
Abstract
PURPOSES Using population kinetic approach, we modeled PSA decline equations in patients with prostate cancer after radical prostatectomy (RP). We looked for relationships between early PSA decrease profile, characterized by PSA clearance (CLPSA) or half-life (HLPSA), and the 2-year biochemical relapse free survival (bRFS). PATIENTS AND METHODS We performed a retrospective study on 55 patients treated with RP and with at least 2 PSA measurements in the post-operative month. A population kinetic model was investigated with NONMEM®. The prognostic factors regarding bRFS were assessed using univariate and multivariate analyses. RESULTS The best model describing the PSA post-operative decrease was bi-compartmental and fit patient data well. Median CLPSA was 0.034 (terciles were 0.023 and 0.048). The significant prognostic factors associated with a better bRFS with univariate analysis were lower CLPSA terciles (2-year bRFS = 100% vs. 85.1% vs. 66.7% if CLPSA < 0.023, 0.023 ≤ CLPSA < 0.048 or CLPSA ≥ 0.0480, P = 0.006) as well as initial PSA < 7 ng/ml, pT2 stage (vs. pT3), pN0 (vs. pN1) and low main Gleason score (3/5 vs. 4/5). Among these factors, CLPSA was the only independent prognostic factor with multivariate analysis regarding bRFS (HR = 0.92, 95%CI = [0.86–0.98], P = 0.0088). CONCLUSION CLPSA determined with 4 PSA concentrations in the first month following the RP may predict the biochemical relapse risk of prostate cancer patients, thus enabling early identification of high-risk patients requiring adjuvant treatment. A prospective validation of these results is required. Prostate 69:1325–1333, 2009.Keywords
This publication has 22 references indexed in Scilit:
- Usefulness of the Serum Carcinoembryonic Antigen Kinetic for Chemotherapy Monitoring in Patients With Unresectable Metastasis of Colorectal CancerJournal of Clinical Oncology, 2008
- Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: A French multicentric studyGynecologic Oncology, 2008
- Overview of model‐building strategies in population PK/PD analyses: 2002–2004 literature surveyBritish Journal of Clinical Pharmacology, 2007
- Are Population Pharmacokinetic and/or Pharmacodynamic Models Adequately Evaluated?Clinical Pharmacokinetics, 2007
- Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized DefinitionJournal of Clinical Oncology, 2006
- Free/Total PSA (F/T ratio) kinetics in patients with clinically localized prostate cancer undergoing radical prostatectomyClinica Chimica Acta, 2005
- Biochemical (Prostate Specific Antigen) Recurrence Probability Following Radical Prostatectomy for Clinically Localized Prostate CancerJournal of Urology, 2003
- Tumor Volume in Prostate Cancer and Serum Prostate-Specific AntigenAmerican Journal of Clinical Pathology, 2003
- Clearance of serum PSA after open surgery for benign prostatic hypertrophy, radical cystectomy, and radical prostatectomyThe Prostate, 1995
- The Population Approach to Pharmacokinetic Data Analysis: Rationale and Standard Data Analysis MethodsDrug Metabolism Reviews, 1984